Elite Pharmaceuticals (OTCMKTS:ELTP) Stock Price Passes Below Two Hundred Day Moving Average – Should You Sell?

Shares of Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.37 and traded as low as $0.2805. Elite Pharmaceuticals shares last traded at $0.2875, with a volume of 261,374 shares traded.

Elite Pharmaceuticals Stock Down 1.2%

The company has a 50-day moving average of $0.35 and a 200-day moving average of $0.37. The company has a market capitalization of $303.00 million, a price-to-earnings ratio of 7.03 and a beta of 0.37. The company has a current ratio of 3.76, a quick ratio of 2.97 and a debt-to-equity ratio of 0.03.

Elite Pharmaceuticals (OTCMKTS:ELTP) last issued its quarterly earnings results on Thursday, August 13th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter. Elite Pharmaceuticals had a return on equity of 44.58% and a net margin of 40.19%.

About Elite Pharmaceuticals

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.